--- title: "U.S. stock market intraday update: Sarepta Therapeutics up 9.35%" description: "Sarepta Therapeutics rose 9.35%; Celcuity rose 175.19%, with a transaction volume of USD 749 million; Gilead Sciences fell 2.47%, with a transaction volume of USD 176 million; Fortress Biotech fell 0." type: "news" locale: "en" url: "https://longbridge.com/en/news/250444813.md" published_at: "2025-07-28T14:43:12.000Z" --- # U.S. stock market intraday update: Sarepta Therapeutics up 9.35% > Sarepta Therapeutics rose 9.35%; Celcuity rose 175.19%, with a transaction volume of USD 749 million; Gilead Sciences fell 2.47%, with a transaction volume of USD 176 million; Fortress Biotech fell 0.47%, with a transaction volume of USD 134 million; AbbVie fell 0.42%, with a market capitalization of USD 334.7 billion **U.S. Stock Market Midday Update** Sarepta Therapeutics, up 9.35%, with increased trading volume. Based on recent key news: 1. On July 25, Sarepta resumed trading, and the stock price turned upward. 2. On July 25, the FDA required Sarepta to conduct more clinical trials to confirm the safety of Elevidys, leading to a significant drop in stock price. 3. On July 28, Barclays downgraded Sarepta's rating to "underweight" due to regulatory updates on Elevidys. **Stocks with High Trading Volume in the Industry** Celcuity, up 175.19%, with a trading volume of $749 million. Based on recent important news: 1. On July 28, Celcuity announced that its three-drug combination therapy outperformed AstraZeneca's treatment in breast cancer trials, significantly reducing the risk of disease progression or death by 76%, driving the stock price up. 2. On July 28, Celcuity reported significant improvements in the primary endpoint of the PIK3CA wild-type cohort in the VIKTORIA-1 trial, planning to submit a new drug application to the FDA in Q4 2025, enhancing market confidence. 3. On July 25, Celcuity launched the VIKTORIA-2 clinical trial, with the first patient already receiving treatment, showing the company's positive progress in breast cancer treatment, boosting investor sentiment. Gilead Sciences, down 2.47%, with a trading volume of $176 million. Based on recent key news: 1. On July 25, EU regulators supported Gilead's biannual injection prevention plan for AIDS, causing the stock price to rise by 2.31%. 2. On July 26, Needham upgraded Gilead's rating to "buy," with a target price of $133, leading to a 2.75% increase in stock price. 3. On July 27, market analysts suggested that Gilead is not the best investment choice currently, resulting in a decline in stock price. Forte Biosciences, down 0.47%, with increased trading volume. Based on recent key news: 1. On July 27, a retail investor frenzy led to a surge in trading volume for small-cap stocks, affecting Forte Biosciences and increasing stock price volatility. 2. On July 28, increased market attention on biotech stocks impacted Forte Biosciences due to its industry position. 3. On July 25, the company announced an increase in quarterly dividends, demonstrating a commitment to shareholder returns, but failed to boost the stock price. **Stocks with High Market Capitalization in the Industry** AbbVie, down 0.42%, with increased trading volume. Based on recent important news: 1. On July 28, AbbVie's cancer drug Rova-T faced clinical failure, shifting reliance to Skyrizi and Rinvoq for growth. Despite solid financials, market confidence in its future growth was affected, leading to a 0.42% decline in stock price 2. On July 26, analysts noted that AbbVie was not on the recommended list. Although rated as a moderate buy, other stocks were considered to have greater investment value, leading to weakened investor confidence. 3. On July 25, there was an increased preference in the market for high-dividend stocks. As a dividend king, AbbVie, despite its high dividend yield, failed to attract sufficient buying interest, putting pressure on its stock price ### Related Stocks - [SRPT.US - Sarepta Therap](https://longbridge.com/en/quote/SRPT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Sarepta 因獲得新西蘭監管機構批准開始亨廷頓病試驗而股價上漲 | Sarepta Therapeutics 的股票在盤前交易中上漲 3%，至 20.92 美元，此前該公司在新西蘭獲得了啓動 SRP-1005 的人體試驗的監管批准，這是一種針對亨廷頓舞蹈症的實驗性治療。該早期試驗將招募約 24 名參與者，重 | [Link](https://longbridge.com/en/news/274824082.md) | | Sarepta 醫療｜8-K：2025 財年 Q4 營收 3.7 億美元不及預期 | | [Link](https://longbridge.com/en/news/272301520.md) | | 展望未來：8 位分析師對 Sarepta Therapeutics 的預測 | 在過去三個月中，8 位分析師對 Sarepta Therapeutics（NASDAQ:SRPT）進行了評估，顯示出從看漲到看跌的情緒範圍。12 個月的平均目標價為 22.25 美元，最高為 45.00 美元，最低為 5.00 美元。最近的 | [Link](https://longbridge.com/en/news/272548848.md) | | 增長前景放緩和監管風險加劇導致對 Sarepta Therapeutics 的賣出評級 | Needham 分析師 Gil Blum 重申了對 Sarepta Therapeutics (SRPT) 的賣出評級，原因是對其增長前景和監管風險的擔憂。儘管 2025 年的收入指引符合預期，但缺乏具體的 2026 年指引引發了對潛在收入 | [Link](https://longbridge.com/en/news/272438221.md) | | Sarepta 醫療第四季度初步淨產品收入未能達到預期 | Sarepta Therapeutics 報告了初步的第四季度淨產品收入為 3.696 億美元，低於分析師預期的 3.8207 億美元。收入受到嚴重流感季節和重新安排的輸液影響。公司在 2025 年結束時擁有 9.538 億美元的現金和投資 | [Link](https://longbridge.com/en/news/272301526.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.